

Revolutionizing Diagnostics with *M. smithii* PCR Test

EPFL Pharmaceutical Biotechnology class presentation

Dr. Duncan Sutherland, Founder & CEO

25.09.2024

ARKAIYA


Foundation of microbiome balance

Overview

- Founded in 2023, at EPFL Innovation Park
- Specializes in microbiome diagnostics for toddlers.
- Flagship product: PCR test for *Methanobrevibacter smithii* (M. smithii), a critical gut archaea.

Foundation of Microbiome Balance ARKAIYA


Foundation of microbiome balance



Why *M. smithii* is a Game Changer

ARKAÏYA

Foundation of microbiome balance



1

Neglected

M. smithii has been largely neglected in microbiome research due to its challenging detection and cultivation, but it plays a pivotal role in gut health

2

Foundational Layer

M. smithii forms the foundational layer of the gut mucous and microbiome, which is essential for proper immune system development and the formation of a healthy microbiome.

3

Critical Biomarker

It is potentially the most relevant biomarker for mucosal health in early life, with significant implications for long-term health.

Impact

- An estimated 1 in 5 toddlers may be deficient in *M. smithii*, affecting their overall health and development.

Market Need

- Microbiome deficiencies in toddlers are linked to various health issues, including compromised mucosal integrity and inflammation.
- Current diagnostic methods are either costly or unreliable.




Our Solution

PCR Test

Product

- Arkaiya SA's semi-quantitative PCR test detects *M. smithii* early, enabling timely intervention.



Web App



Patented

Invisible Yet Foundational

- M. smithii* has long been "invisible" due to its unusual hard cell wall, making it difficult to detect with standard analytics. Additionally, its anaerobic cultivation is highly challenging, leading to its neglect in mainstream research.

Breakthrough Innovation

- Arkaiya SA, in collaboration with our partners, has pioneered methods that successfully detects and cultivates *M. smithii*, opening new avenues in health diagnostics and therapeutics.


Foundational Layer of the Microbiome

- *M. smithii* forms a foundational layer in the human microbiome, becoming the most dominant species of the colon in healthy adults, with up to 10% relative abundance.

Critical Biomarker

- Toddlers with low levels of *M. smithii* may be advised to take supplements like HMOs (human milk oligosaccharides) to promote this foundational layer, enhancing mucosal health and overall microbiome formation.

Microbiome Diagnostic Market Projection



Target Customers




Competitive Landscape

=> none focus specifically on *M. smithii*.

V I O M E

synlogic


SECOND GENOME



Business & Revenue Model


ARKAIYA
Foundation of microbiome balance

Price Point Advantage




Profitability

CHF 100.- per kit



Sales Targets



Funding Strategy



\$ 1.5 Million

- Further development
- Validation
- Market launch

2025



MS1
PCR Launch

\$ 3-5 Million

2026




MS2
International
Expansion

MS3
Complementary
Products



Milestones & Achievements



Executive Team

ARKAÏYA

Foundation of microbiome balance

- **Dr. Duncan Sutherland CEO**
10+ years in gastro immunology R&D,
5+ years in entrepreneurship, inventor of 6 patents.

- **Prof. Hiroshi Ohno**
Board Member
Dep. Director RIKEN IMS



- **Dr. Shohei Asami**
Microbiome scientist,
PCR diagnostics expert.



- **Dr. Axel Martinelli**
Molecular biologist,
scientific advisor.



- **Mr Alessandro Mavilio**
Software engineer,
Web platform manager.



- **Mr Swithun Still**
Board Member
(former GAFTA President)



Why Arkaiya?

ARKAIYA
Foundation of microbiome balance

Arkaiya is set to transform early childhood microbiome health

'Arkaiya SA, is pioneering in its field but is also poised to revolutionize early childhood microbiome health.'

Join us in revolutionizing microbiome health.'

TEDx Ecublens 2024

Hidden role of archaea in the gut microbiome




Follow-up questions:

Dr. Duncan Sutherland, duncan@arkaiya.com

Additional information

A-1. Human milk oligosaccharides (HMO) ↑ archaea

ARKAIYA
Foundation of microbiome balance



A-2. Archaea missing in malnourished infants






Figure. Study Mali Cohort
110 healthy, 143 malnourished

A-3.Archaea supports mucosal defense



Colonization resistance
Salmonella Typhimurium
(strain SL1344 ΔinvC AssaV)



In vivo mouse model
Gnotobiotic mice
12 bacteria + *M. smithii*

A-4. Patent portfolio

Category	Description	ID	Status	Regions.
Probiotic	Use of archaea in human food	US20180193390A1	Granted 2019	Worldwide
Postbiotic	Use of inactivated archaea for immune regulation	WO2020002543A1	Granted 2023	US EU JP
Diagnostic	Archaea as a biomarker and therapeutic for immune health in early life	WO/2023/170262	Filed 2023	US EU JP CH

A-5. OlogioMM12 gnotobiotic mice (preclinical)


ARKAİYA


Foundation of microbiome balance

Acutalibacter muris	KB18
Akkermansia muciniphila	YL44
Bacteroides caecimuris	I48
Bifidobacterium animalis	YL2
Blautia coccoides	YL58
Clostridium innocuum	I46
Enterocloster clostridioformis	YL32
Enterococcus faecalis	KB1
Flavonifractor plautii	YL31
Limosilactobacillus reuteri	I49
Muribaculum intestinale	YL27
Turicimonas muris	YL45
Methanobrevibacter smithii	DSM861

A-6. *M. smithii* archaea promotes beneficial bacteria

M. smithii treatment regulates microbiome composition





GUT LINING

Immune Cells


1. Microbe patterns

2. Pattern recognition

3. Signals

4. Immune hormones 'Cocktail'


5. Immune System Education




Infant

Toddlers
Age 1 - 4 years


Adult



20240703 Msmithii *mnif* gene PCR Results (non-freeze dried)



20240829 Msmithii mnif gene PCR Results (lyophilize + DDW)



➤ **Archaea inversely associated with childhood asthma (n = 496)**

Barnett et al, Intestinal archaea inversely associated with childhood asthma, *J Allergy & Clin Immunology*, 2019

➤ **Archaea inversely associated with inflammatory bowel disease**

Ghavami et al, Alterations of the human gut *Methanobrevibacter smithii* as a biomarker for inflammatory bowel diseases, *Microb Pathog*, 2018

➤ **Archaea inversely associated with colorectal cancer in aged 50+**

Coker et al, Altered gut archaea composition and interaction with bacteria are associated with colorectal cancer, *Gastroenterology*, 2019

➤ **Archaea inversely associated with atopic dermatitis**

Melli et al, Gut microbiota of children with atopic dermatitis: Controlled study in the metropolitan region of Sao Paulo, Brazil, *Allergy & Immunopathology*, 2020

➤ **Keystone archaea species are in mother's milk and essential to baby's health**

Togo et al, Culture of Methanogenic Archaea from Human Colostrum and Milk, *Scientific Reports*, 2019

➤ **Keystone archaea species in newborn gastric juices**

Grine et al, *Methanobrevibacter smithii*, a methanogen consistently colonising the newborn stomach, *European J of Clinical Microbiology & Inf. Diseases*, 2017

➤ **Archaea colonization associated with organic dairy milk consumption**

Van de Pol et al, Gut colonization by methanogenic archaea is associated with organic dairy consumption in children, *Frontiers in Microbiology*, 2017

➤ **Archaea colonization inversely associated with obese-associated microbiota (inflamed phenotype)**

Million et al, Obesity-associated gut microbiota is enriched in *Lactobacillus reuteri* and depleted in *Bifidobacterium animalis* and *M. smithii*, *Int J of Obesity*, 2012